Search clinical trials for: Darunavir (DRV)

Total 230 results

Prof. Dr. Frank Mooren

Completed

Whole-body Electromyostimulation in Inpatient Rehabilitation (GERKO)

Sarcopenia

Germany
University of Kiel
Fachklinik Satteldüne der DRV Nord; University of Kiel, Arbeitsbereich Sportmedizin... and other collaborators

Active, not recruiting

Effects of Training Intensity on Physical Fitness and Body Composition in Cystic Fibrosis

Cystic Fibrosis

Germany
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Healthy

Germany
Massachusetts General Hospital
National Heart, Lung, and Blood Institute (NHLBI); University of Aarhus

Recruiting

Supplemental Oxygen in Pulmonary Embolism (SO-PE) (SO-PE)

Venous Thromboembolism | Pulmonary Embolism | Metabolomics | Oxygen Inhalation Therapy

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

HIV Infections
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
PENTA Foundation
Institut National de la Santé Et de la Recherche Médicale, France; MRC CTU... and other collaborators

Completed

Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children (SMILE)

HIV Infection

United Kingdom, Spain, Argentina, France, Mexico, Portugal, South Africa, Switzerland, Thailand, Uganda, Ukraine
Galderma R&D

Completed

Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane

Atrophy

France
PENTA Foundation
Baylor College of Medicine; Institut National de la Santé Et de la Recherche... and other collaborators

Not yet recruiting

Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (UNIVERSAL2)

HIV Infections
ASST Fatebenefratelli Sacco
Elisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.

Completed

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Human Immunodeficiency Virus

Italy
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy (DRV900100QD)

HIV Infections

Spain
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

HIV-1 Infection

Spain
A.O. Ospedale Papa Giovanni XXIII
San Raffaele University Hospital, Italy

Unknown

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection (PROBE2)

HIV Infection

Italy
Willem Daniel Francois Venter
Medical Research Council, South Africa

Completed

Evaluation of Low-dose Darunavir in a Switch Study (DRV)

HIV Infections

South Africa
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants

Healthy

Belgium
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
ViiV Healthcare

Completed

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

HIV Infections

United States
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Janssen-Cilag G.m.b.H

Completed

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)

Human Immunodeficiency Virus (HIV)

Germany
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

Human Immunodeficiency Virus - Type 1

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
Community Research Initiative of New England

Completed

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors (DVD)

HIV Infections

United States
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (DETOX)

HIV Infections

Spain
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice (CoDAR)

HIV Infections

Spain
Janssen-Cilag S.p.A.

Completed

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients (MONARCH)

Human Immunodeficiency Virus 1
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.

HIV | AIDS
Janssen Sciences Ireland UC

Completed

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

HIV-1 Infections

France, Ukraine, South Africa, United Kingdom, Argentina, Brazil, India, Spain
Gilead Sciences

Completed

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Janssen Sciences Ireland UC

Completed

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

HIV-1 Infections

Costa Rica, Panama, South Africa, Ukraine, Malaysia, Brazil, Thailand, Guatemala
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Multiple Myeloma

United States
Wolfgang Gaebel, Professor
German Federal Ministry of Education and Research

Completed

Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM) (STEM)

Depression | Schizophrenia

Germany
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Janssen-Cilag Ltd.

Completed

Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

HIV-1

Taiwan
Boehringer Ingelheim

Terminated

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

HIV Infections

United States, Bahamas, Belgium, Canada, France, Germany, Greece, Italy, Portugal, Puerto Rico, Spain, Thailand
Janssen Research & Development, LLC

Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Human Immunodeficiency Virus (HIV)

United States, Spain, South Africa
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Gilead Sciences

Recruiting

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, South Africa, Argentina, Panama, Thailand, Zimbabwe, United Kingdom, Uganda
Gilead Sciences
Janssen Research & Development, LLC

Completed

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Community Research Initiative of New England
Tibotec Pharmaceutical Limited

Completed

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r (LARD)

HIV Infections

United States
Janssen-Cilag S.p.A.

Completed

Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (STORE)

Human Immunodeficiency Virus
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

Hepatitis C Virus

Belgium
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

HIV-1 Infection

Kenya, Brazil, South Africa, Uganda, Zimbabwe, India, Malawi, Haiti, Thailand, Peru
Janssen Korea, Ltd., Korea

Completed

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

Acquired Immune Deficiency Syndrome

Korea, Republic of
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Completed

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. (ROaR+)

Cardiovascular Disease | HIV

Australia
Gilead Sciences

Completed

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

HIV Infections | Acquired Immunodeficiency Syndrome

Puerto Rico, United States, United Kingdom, Canada, Germany, Austria, Australia, Dominican Republic, Mexico
Gilead Sciences

Terminated

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

HIV-1-infection

Uganda, Zimbabwe
Janssen Research & Development, LLC

Completed

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Healthy

Belgium
Juan A. Arnaiz

Unknown

Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (RALAM)

AIDS

Spain

3

Subscribe